Abstract:
:Adoptive cell transfer immunotherapy against melanoma is highly effective. However, this therapy has seen limited dissemination, mainly due to the complexity and costs of cell expansion protocols. Two bioreactors have recently been described that simplify and streamline the production of individualized cell therapies. Such bioreactors might increase the number of patients that get access to this promising therapeutic modality.
journal_name
Oncoimmunologyjournal_title
Oncoimmunologyauthors
Somerville RP,Dudley MEdoi
10.4161/onci.21206subject
Has Abstractpub_date
2012-11-01 00:00:00pages
1435-1437issue
8eissn
2162-4011issn
2162-402Xpii
2012ONCOIMM0204journal_volume
1pub_type
杂志文章相关文献
OncoImmunology文献大全abstract::The elicitation of efficient antitumor immune responses requires the optimal activation of tumor-associated dendritic cells (DCs). Our comparison of the effect of various immunostimulatory treatments on DCs revealed that the best predictor of the success of immunotherapy is not the activation of existing DC population...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.4161/onci.26443
更新日期:2013-11-01 00:00:00
abstract::β-glucans are complex, naturally-occurring polysaccharides that prime leukocyte dectin and complement receptor 3. Based on our preclinical findings, indicating that oral barley-derived (1 → 3),(1 → 4)-β-D-glucan (BG) synergizes with the murine anti-GD2 antibody 3F8 against neuroblastoma, we conducted a Phase I clinica...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.4161/onci.23402
更新日期:2013-03-01 00:00:00
abstract::Macrophages promote the growth of leiomyosarcoma (LMS), a malignant soft-tissue tumor. CD47 on tumor cells binds to the macrophagic receptor signal regulatory protein α (SIRPα) and prevents phagocytosis. We showed that anti-CD47 monoclonal antibodies (mAbs) allow macrophages to engulf LMS cells and prevent tumor growt...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.4161/onci.20799
更新日期:2012-10-01 00:00:00
abstract::The immune contexture, a composition of the tumor microenvironment, plays multiple important roles in cancer stem cell (CSC) and epithelial-mesenchymal transition (EMT), and hence critically influences tumor initiation, progression and patient outcome. Tumor-associated macrophages (TAMs) are abundant in immune context...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.1080/2162402X.2017.1380765
更新日期:2017-10-11 00:00:00
abstract::Regulatory T cell (Treg) promote IL-17-mediated colon tumorigenesis in multiple intestinal neoplasia (Min) mice colonized with enterotoxigenic Bacteroides fragilis (ETBF). Although they retain their immunosuppressive function, mucosal Treg are instrumental to initiate ETBF-triggered IL-17 colitis by limiting the avail...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.1080/2162402X.2015.1118601
更新日期:2015-12-21 00:00:00
abstract::PolyI:C is a nucleotide pattern molecule that induces cross-presentation of foreign Ag in myeloid dendritic cells (DC) and MHC Class I-dependent proliferation of cytotoxic T lymphocytes (CTL). DC (BM or spleen CD8α(+)) have sensors for dsRNA including polyI:C to signal facilitating cross-presentation. Endosomal TLR3 a...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.4161/onci.19893
更新日期:2012-08-01 00:00:00
abstract::It was previously demonstrated that engineered mesenchymal stem cells (MSCs) which express a high level of a very efficient modified gene CYP2B6* (CYP2B6TM-RED) acting as a suicide gene (MSC-2B6*) in combination with cyclophosphamide (CPA) constitute a powerful cell/gene therapy approach for solid tumors. In murine mo...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.1080/2162402X.2019.1667743
更新日期:2019-09-27 00:00:00
abstract::Macrophages in the tumor microenvironment respond to complex cytokine signals. How these responses shape the phenotype of tumor-associated macrophages (TAMs) is incompletely understood. Here we explored how cytokines of the tumor milieu, interleukin (IL)-6 and IL-4, interact to influence target gene expression in prim...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.1080/2162402X.2018.1494110
更新日期:2018-07-30 00:00:00
abstract::Immunotherapies targeting programmed cell death protein 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), dramatically improve the survival of melanoma patients. However, only ∼40% of treated patients demonstrate a clinical response to single-agent anti-PD-1 therapy. An intact tumor response to type-II i...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.1080/2162402X.2018.1438106
更新日期:2018-03-06 00:00:00
abstract::Dendritic cells (DCs) occupy a privileged position at the interface between innate and adaptive immunity, orchestrating a large panel of responses to both physiological and pathological cues. In particular, whereas the presentation of antigens by immature DCs generally results in the development of immunological toler...
journal_title:Oncoimmunology
pub_type: 评审
doi:10.4161/onci.25771
更新日期:2013-10-01 00:00:00
abstract::Background. Immunotherapy has shown efficacy in small cell lung cancer (SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently needed. Our aim was to evaluate serum Th1, Th2, and proinflammatory cytokines in two cohorts of SCLC patients before and during treatment with chemotherapy with or wi...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.1080/2162402X.2019.1593810
更新日期:2019-03-27 00:00:00
abstract::The generation and loading of dendritic cells (DC) ex-vivo for tumor vaccination purposes is laborious and costly. Direct intradermal (i.d.) administration of tumor-associated antigens could be an attractive alternative approach, provided that efficient uptake and cross-presentation by appropriately activated skin DCs...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.4161/21624011.2014.946360
更新日期:2014-07-03 00:00:00
abstract::Five-year survival rates for patients diagnosed with metastatic melanoma are less than 5%. Adoptive cell transfer (ACT) has achieved an objective response of 50% by Response Evaluation Criteria in Solid Tumors (RECIST) in this patient population. For ACT to be maximally effective, the host must first be lymphodepleted...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.1080/2162402X.2015.1019196
更新日期:2015-04-01 00:00:00
abstract::Combination therapies with phosphoinositide 3-kinase (PI3K) inhibitors and trastuzumab (anti-human epidermal growth factor receptor [HER]2/neu antibody) are effective against HER2+ breast cancer. Isoform-selective PI3K inhibitors elicit anti-tumor immune responses that are distinct from those induced by inhibitors of ...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.1080/2162402X.2017.1421890
更新日期:2018-01-16 00:00:00
abstract::Egfl7 is an endothelial-specific gene which expression is deregulated in human cancers. We showed that Egfl7 promotes tumor escape from immunity by downregulating the expression of leukocyte adhesion molecules in endothelial cells, thus repressing immune cell extravasation into tumors. ...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.4161/onci.18964
更新日期:2012-05-01 00:00:00
abstract::The redirection of T cell activity using bispecific antibodies is one of the most promising cancer immunotherapy approaches currently in development, but it is limited by cytokine storm-related toxicities, as well as the pharmacokinetics and tumor-penetrating capabilities of current bispecific antibody formats. Here, ...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.1080/2162402X.2017.1377874
更新日期:2017-09-27 00:00:00
abstract::The benefits of anti-cancer agents extend beyond direct tumor killing. One aspect of cell death is the potential to release antigens that initiate adaptive immune responses. Here, a diffusion enhanced formulation, INT230-6, containing potent anti-cancer cytotoxic agents, was administered intratumorally into large (app...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.1080/2162402X.2019.1625687
更新日期:2019-07-16 00:00:00
abstract::Agonistic tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-receptor-specific antibodies are attractive antitumor therapeutics. Recently, our group has generated several human monoclonal antibodies (mAbs) to TRAIL-receptor-1 (TRAIL-R1) (TR1-IgGs) using ISAAC technology. However, these TR1-IgGs did ...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.1080/2162402X.2015.1131380
更新日期:2016-05-04 00:00:00
abstract::Oncolytic virotherapy is an emergent promising therapeutic approach for the treatment of cancer. We have constructed a vaccinia virus (WR strain) deleted for thymidine kinase (TK) and ribonucleotide reductase (RR) genes that expressed the fusion suicide gene FCU1 derived from the yeast cytosine deaminase and uracil ph...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.1080/2162402X.2015.1080414
更新日期:2015-10-06 00:00:00
abstract::Naïve T cells activated by antigen-presenting cells (APC) can be differentiated into at least four major types of T-helper (T(H)) cells: T(H)1, T(H)2, T(H)17 and inducible regulatory T cells (iTreg) based on their unique cytokine production profiles and characteristic functions.(1) T(H)1 produce interferon-γ (IFNγ) an...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.4161/onci.19457
更新日期:2012-07-01 00:00:00
abstract:BACKGROUND:Ipilimumab has proven to be effective in metastatic melanoma patients. The purpose of this study was to determine the efficacy of ipilimumab in advanced melanoma patients who showed progressive disease upon experimental dendritic cell (DC) vaccination. METHODS:Retrospective analysis of 48 stage IV melanoma ...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.1080/2162402X.2016.1201625
更新日期:2016-06-17 00:00:00
abstract::Adoptive cell transfer (ACT) is an emerging anticancer therapy that has shown promise in various malignancies. Redirecting antigen specificity by genetically engineering T cells to stably express receptors has become an effective variant of ACT. A novel extension of this approach is to utilize engineered T cells to pr...
journal_title:Oncoimmunology
pub_type: 杂志文章,评审
doi:10.1080/2162402X.2015.1122158
更新日期:2016-01-15 00:00:00
abstract::Dendritic cell (DC)-based vaccines against cancer have been extensively developed over the past two decades. Typically DC-based cancer immunotherapy entails loading patient-derived DCs with an appropriate source of tumor-associated antigens (TAAs) and efficient DC stimulation through a so-called "maturation cocktail" ...
journal_title:Oncoimmunology
pub_type: 杂志文章,评审
doi:10.1080/2162402X.2017.1328341
更新日期:2017-05-12 00:00:00
abstract::The alarmin IL-33 is an IL-1 family member that stimulates pleiotropic immune reactions depending on the target tissue and microenvironmental factors. In this study, we have investigated the role of IL-33/ST2 axis in antitumor response to melanoma. Injection of IL-33 in mice-bearing subcutaneous B16.F10 melanoma resul...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.1080/2162402X.2017.1317420
更新日期:2017-04-20 00:00:00
abstract::NY-ESO-1 (CTAG 1B) is highly expressed in the majority of synovial sarcomas and myxoid/round cell liposarcomas as well as in a subset of melanomas, but only rarely in other mesenchymal tumors. This points to a potential for using NY-ESO-1 in the differential diagnosis of these lesions. Furthermore, promising results h...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.4161/onci.21059
更新日期:2012-11-01 00:00:00
abstract::Low expression of RhoGDI2 is associated with poor outcome in cancer patients. In animal models, RhoGDI2 suppresses lung metastasis by reducing the expression of the proteoglycan versican, whose levels portend poor patient prognosis. Versican promotes metastasis through enhanced tumor migration and creation of an infla...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.4161/onci.20594
更新日期:2012-10-01 00:00:00
abstract::Chimeric antigen receptor (CAR) T cells have enjoyed unprecedented clinical success against haematological malignancies in recent years. However, several aspects of CAR T cell biology remain unknown. We recently compared CAR and T cell receptor (TCR)-based killing in the same effector cell and showed that CAR T cells ...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.1080/2162402X.2015.1053684
更新日期:2015-06-01 00:00:00
abstract::Surgical resection is the mainstay of treatment for solid tumors, but the postoperative period is uniquely inclined to the formation of metastases, largely due to the suppression of natural killer (NK) cells. We found that preoperative influenza vaccination prevents postoperative NK-cell dysfunction, attenuating tumor...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.4161/onci.26618
更新日期:2013-11-01 00:00:00
abstract::Estrogen receptors have recently been demonstrated at the cell surface. Unlike nuclear receptors, they are able to trigger rapid responses inside the cells. In this study, we evaluated the presence and the possible role of autoantibodies specific to estrogen receptor (anti-ER Abs) in the peripheral blood of breast can...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.1080/2162402X.2015.1074375
更新日期:2015-08-12 00:00:00
abstract::Preclinical data suggest that a "prime-boost" vaccine regimen using a target-expressing lentiviral vector for priming, followed by a recombinant protein boost, may be effective against cancer; however, this strategy has not been evaluated in a clinical setting. CMB305 is a prime-boost vaccine designed to induce a broa...
journal_title:Oncoimmunology
pub_type: 杂志文章
doi:10.1080/2162402X.2020.1847846
更新日期:2020-11-19 00:00:00